Aerovance names new senior vice president and chief medical officer

Prior to joining Aerovance, Dr Otulana worked with Aradigm, where he most recently served as senior vice president, development, and chief medical officer.

Dr Otulana will provide medical as well as organizational and regulatory leadership to the company as it moves forward with the development of Aerovant for uncontrolled asthma and Aeroderm for severe atopic eczema.

Mark Perry, president and CEO of Aerovance, said: “Tunde has a wealth of experience in the planning and implementation of clinical development programs for pulmonary drugs. He will focus on advancing Aerovant through clinical development, beginning with our upcoming Phase IIb clinical trial in patients living with uncontrolled asthma, while further developing Aerovance’s pipeline.”